Glucose Transporter Type 1 Deficiency Syndrome
14
1
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.1%
1 terminated out of 14 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome
Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
Early Check: Expanded Screening in Newborns
The Glucose Transporter Type I Deficiency (G1D) Registry
Evaluation of Keyo in Children With Epilepsy
Evaluation of Krio in Children and Adults With Epilepsy
Evaluation of Ketoflo
Brain Metabolism Observed at 7 Tesla
Treatment Development of Triheptanoin (G1D)
Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)
Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
Post Study Continuation of C7 for G1D
Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)
Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome